As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
11 Analysts have issued a Ginkgo Bioworks forecast:
11 Analysts have issued a Ginkgo Bioworks forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 181 181 |
17%
17%
|
|
| Gross Profit | 131 131 |
26%
26%
|
|
| EBITDA | -278 -278 |
23%
23%
|
|
| EBIT (Operating Income) EBIT | -339 -339 |
20%
20%
|
|
| Net Profit | -340 -340 |
48%
48%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Jason Kelly |
| Employees | 834 |
| Founded | 2008 |
| Website | investors.ginkgobioworks.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


